Neurológia pre prax 1/2017

Aubagio (teriflunomid) jako jedna z možností léčby u mužů s roztroušenou sklerózou

Aubagio is one of the treatment options in multiple sclerosis. The active substance is teriflunomide that inhibits the mitochondrial enzyme dihydroorotate dehydrogenase. It is the only first-line oral medication and is taken at a dose of 14 mg once a day. It is a suitable drug of choice, among other things, in young men actively engaged in sport and work, particularly due to the fact of it being an oral medication with a very good safety profile. Three case reports are presented with the aim to document the effect of teriflunomide. All the patients are young men who have been on the treatment for several years.

Keywords: teriflunomide, Aubagio, multiple sclerosis, clinically isolated syndrome